secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001493152-23-017646
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q1 revenue up 4.7% to $1.24M; net loss $4.3M; completed $42.2M private placement
--------------------------------------------------------------------------------

- Q1 2023 revenue $1.239M (+4.7% YoY); CGuard EPS revenue $1.239M (+6.7% YoY); net loss $4.256M ($0.53/sh).
- Cash & equivalents $12.9M as of March 31, 2023; subsequent to quarter, completed $42.2M upfront private placement for up to $113.6M.
- CE Mark reinstated under MDD in mid-March; shipments resumed; working through backlog; awaiting MDR recertification.
- US IDE trial enrollment on track to complete by end of Q2 2023; FDA approved CGuard Prime delivery system for trial.
- Hired Shane Gleason as GM of North America and VP Global Marketing; promoted Andrea Tommasoli to COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223017646/0001493152-23-017646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223017646/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-017646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer